Trends in the commercial development of antibody therapeutics: The early-stage clinical pipeline
723 بار بازدید -
10 ماه پیش
-
Speaker: Silvia Crescioli, PhD.Since 2014,
Speaker: Silvia Crescioli, PhD.
Since 2014, the number of antibody therapeutics entering clinical development annually has increased steadily, from 71 in 2014 to 286 in 2022. This has resulted in a clinical pipeline currently composed of ~1250 molecules, of which ~1100 and ~150 molecules are in early- and late-stage development, respectively. Despite the great interest in trends in early-stage clinical development, due to the difference in scale and difficulty in tracking molecules newly entered in clinical studies, analyses of trends in the global commercial development of antibody therapeutics are often limited to the late-stage clinical pipeline only. Luckily, The Antibody Society meticulously collects data for antibody therapeutics at all stages of clinical development. This webinar will provide an exhaustive analysis of the early-stage pipeline stratified by cancer and non-cancer indications, revealing trends in the molecular formats, targets, and mechanism of action.
About the speaker: Silvia Crescioli is a Consultant for The Antibody Society and chair of The Antibody Society Communication and Membership Committee. Since 2021 she has co-authored the "Antibodies to watch" articles in published in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody therapeutics marketing application submission as well as approvals that might occur the following year. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence in 2014, followed by eight years as a post doc at King's College London in Prof. Karagiannis' Cancer Antibody Discovery & Immunotherapy Group, where she is now a visiting Research Fellow. Her research interests focus on antibody therapeutics development for both cancer and noncancer indications, as well as on different areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering and glycoengineering.
Since 2014, the number of antibody therapeutics entering clinical development annually has increased steadily, from 71 in 2014 to 286 in 2022. This has resulted in a clinical pipeline currently composed of ~1250 molecules, of which ~1100 and ~150 molecules are in early- and late-stage development, respectively. Despite the great interest in trends in early-stage clinical development, due to the difference in scale and difficulty in tracking molecules newly entered in clinical studies, analyses of trends in the global commercial development of antibody therapeutics are often limited to the late-stage clinical pipeline only. Luckily, The Antibody Society meticulously collects data for antibody therapeutics at all stages of clinical development. This webinar will provide an exhaustive analysis of the early-stage pipeline stratified by cancer and non-cancer indications, revealing trends in the molecular formats, targets, and mechanism of action.
About the speaker: Silvia Crescioli is a Consultant for The Antibody Society and chair of The Antibody Society Communication and Membership Committee. Since 2021 she has co-authored the "Antibodies to watch" articles in published in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody therapeutics marketing application submission as well as approvals that might occur the following year. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence in 2014, followed by eight years as a post doc at King's College London in Prof. Karagiannis' Cancer Antibody Discovery & Immunotherapy Group, where she is now a visiting Research Fellow. Her research interests focus on antibody therapeutics development for both cancer and noncancer indications, as well as on different areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering and glycoengineering.
10 ماه پیش
در تاریخ 1402/08/03 منتشر شده
است.
723
بـار بازدید شده